Trial record 11 of 26 for:
rhBMP-2 | Industry
Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
This study has been terminated.
Sponsor:
Medtronic Spinal and Biologics
Information provided by (Responsible Party):
Medtronic Spinal and Biologics
ClinicalTrials.gov Identifier:
NCT01494493
First received: December 12, 2011
Last updated: December 15, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this clinical trial is to evaluate the implant (rhBMP-2/ACS/allograft bone dowel) as a method of facilitating spinal fusion in patients with degenerative disc disease.
| Condition | Intervention |
|---|---|
|
Degenerative Disc Disease |
Procedure: rhBMP-2/ACS/allograft bone dowel Procedure: Autogenous bone/allograft bone dowel |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease |
Further study details as provided by Medtronic Spinal and Biologics:
Primary Outcome Measures:
- Overall success [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
A patient will be considered an overall success if all of the following conditions are met:
- fusion;
- pain/disability (Oswestry) improvement;
- maintenance or improvement in neurological status;
- no serious adverse event classified as implant associated or implant/surgical procedure associated;
- no additional surgical procedure classified as a "failure."
Secondary Outcome Measures:
- Disc Height Measurement [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- General Health Status (SF-36) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Back and Leg Pain Status (Numerical Rating Scale) [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient Satisfaction [ Time Frame: 24 month ] [ Designated as safety issue: No ]
- Patient Global Perceived Effect [ Time Frame: 24 month ] [ Designated as safety issue: No ]
| Enrollment: | 85 |
| Study Start Date: | September 2000 |
| Study Completion Date: | February 2004 |
| Primary Completion Date: | February 2004 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: rhBMP-2/ACS |
Procedure: rhBMP-2/ACS/allograft bone dowel
The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
Other Name: Recombinant human bone morphogenetic protein-2
|
| Active Comparator: Autogenous Bone |
Procedure: Autogenous bone/allograft bone dowel
An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
Other Name: Autograft
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit)and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
- instability( defined as angular motion > 5° and/or translation >= 2-4mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score > 35.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
- Has single-level symptomatic degenerative involvement from L4 to S1.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Had previous anterior spinal fusion surgical procedure at the involved level.
- Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids or nonsteroidal antiinflammatory drugs (this does not include low dose aspirin for prophylactic anticoagulation or perioperative steroids).
- Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
- Has overt or active bacterial infection, either local or systemic.
- Is obese, i.e., weight greater than 40% over ideal for their age and height.
- Has fever (temperature> 101°F oral) at the time of surgery.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse.
- Is a tobacco user at the time of surgery.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of exposure to injectable collagen implants.
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Has received any previous exposure to any/all BMP's of either human or animal extraction.
- Has a history of allergy to bovine products or a history of anaphylaxis.
- Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Medtronic Spinal and Biologics |
| ClinicalTrials.gov Identifier: | NCT01494493 History of Changes |
| Other Study ID Numbers: | P00-01 |
| Study First Received: | December 12, 2011 |
| Last Updated: | December 15, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Medtronic Spinal and Biologics:
|
symptomatic degenerative disc disease |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 19, 2013